• Patient Site
  • V-Go Customer Care
vgo green
  • Call 1-866-881-1209
  • About V-Go
    • What is V-Go®?
    • Who is it For?
    • How it Works
    • Why V-Go®?
    • Authorized Distributors
  • Clinical Data
    • Optimize Delivery
    • Efficacy
    • Insulin Reduction
    • Patient Adherence
  • Prescribing & Dosing
    • Overview
  • Patient Support
    • Starting Patients
    • Comprehensive Support for You and Your Patients
    • Common Patient Questions
  • Coverage & Savings
    • Overview
  • Pharmacists
    • Overview
    • Reimbursement Card

Overview to Start Patients on V-Go®

Prescribing V-Go for Your Adult Patients Who Require Insulin

V-Go requires only 1 insulin type. A U-100 fast-acting insulin should be used. Humalog® (insulin lispro, rDNA origin) and NovoLog® (insulin aspart, rDNA origin) have been tested and found to be safe for use in the V-Go Wearable Insulin Delivery Device.

V-Go is available as a 30-day supply in 3 options—V-Go 20, V-Go 30, and V-Go 40.

Three basal rate options to best meet patient needs

Each option includes up to 36 units for bolus dosing.

†1 click = 2 Units.
‡You can only click the Bolus Delivery Button 18 times in every 24-hour period, for up to 36 U/day. Each click of the Bolus Delivery Button delivers 2 Units of insulin.

V-Go dosing options

Determine the starting dose and titrate as needed

Titration Guidance

  • Optimize Bolus Dosing
    • If mealtime glucose remains elevated, add an additional click (2 units).
  • Titrate Basal
    • If bolus dosing is optimized and A1c or fasting glucose remains elevated, adjust V-Go basal dose.

Recommended to evaluate insulin dosing within 2-5 days of initiating V-Go and to ensure that patients have a plan to manage hypoglycemia and hyperglycemia.

†Individual dosing needs may vary

Understand the total daily dose of insulin your patient is actually taking with their current insulin regimen versus what is being prescribed. Selecting the correct V-Go option may lessen the risk of hypoglycemia (low blood sugar).

It is common practice to reduce the total daily insulin dose when starting a patient on continuous subcutaneous insulin infusion therapy, and this reduction should be considered when starting a patient on V-Go.

V-Go dosing guidance

V-Go Blood Sugar Log and Titration Tool

As with any insulin therapy, titration with V-Go is critical to improving glycemic control. This V-Go blood sugar log helps patients track their blood sugar and adjust their weekly mealtime clicks. This resource is also available in Spanish.

Download                    Download in Spanish

Get your patients started with 2 prescriptions

When starting a patient on V-Go, 2 prescriptions are needed. Write 1 prescription for V-Go and another prescription for the U-100 fast-acting insulin. Two vials of insulin are required for V-Go 20, and 3 vials of insulin are required for V-Go 30 and V-Go 40.

*A U-100 fast-acting insulin should be used with V-Go. Humalog® (insulin lispro [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection) have been tested and found to be safe for use in V-Go.2
†Be sure to click Humalog® or NovoLog®. Click “unstructured” and type in the Sig, Disp, and Pharmacy Notes manually. Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.

References: 1. Data on file–Zealand Pharma A/S 2017. 2. Instructions for Patient Use. P/N 2614-00 Rev. A 05/2019.

Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.

  • Product Specs
  • Important Safety Information
  • Contact Us
  • Zealand Pharma
  • Terms of Use & Privacy
  • Cookies
  • Site Map
  • Twitter
  • YouTube
Zealand Pharma Logo Neg (Mar2020) 316x116
White V-Go® logo
© 2021 Zealand Pharma A/S
This website uses cookies to improve your browsing experience. Read MoreAccept
Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.